Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."
Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.
Discover This Company's MASSIVE Lithium Opportunit

CNTX Insider Trading (Context Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $65,000.00
Insider Selling (Last 12 Months): $0.00

Context Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Share Price & Price History

Current Price: $5.65
Price Change: Price Increase of +0.55 (10.78%)
As of 11/29/2021 02:07 PM ET

This chart shows the closing price history over time for CNTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock

Context Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/22/2021Alex C. LevitInsiderBuy3,000$5.00$15,000.00View SEC Filing Icon  
10/22/2021Martin A. LehrCEOBuy10,000$5.00$50,000.00View SEC Filing Icon  
See Full Table
Insider Selling at Context Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Context Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.
Read More on Context Therapeutics

Today's Range

Now: $5.65
Low: $5.09
High: $5.65

50 Day Range

MA: N/A

52 Week Range

Now: $5.65
Low: $4.32
High: $8.29

Volume

8,320 shs

Average Volume

3,292,414 shs

Market Capitalization

$57.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Context Therapeutics?

Context Therapeutics' top insider shareholders include:
  1. Alex C Levit (Insider)
  2. Martin A Lehr (CEO)
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."
Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.
Discover This Company's MASSIVE Lithium Opportunit